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COOPERATIVITY OF CCNE1 AND FOXM1 IN HIGH-GRADE SEROUS
OVARIAN CANCER

ABSTRACT
Lucy G. Elge, M.S.
University of Nebraska Medical Center, 2020
Supervisor: Adam R. Karpf, Ph.D.

High-grade serous ovarian cancer (HGSC) ranks as the fifth leading cause of
female cancer related deaths. A greater understanding of the molecular mechanisms
underlying HGSC will elucidate better detection methods and identify potential treatment
targets.
Forkhead Box M1 (FOXM1) is a key player in HGSC, as data from The Cancer
Genome Atlas (TCGA) revealed that its activation is the second most frequent molecular
alteration in HGSC. Similarly, cyclin E1 (CCNE1) is also important in HGSC, as the gene
is amplified in 20% of HGSC cases. Both genes and proteins have been studied
extensively, but the potential interaction between the two has not been examined in HGSC
progression or in other cancer models.
We found that dual ectopic expression of CCNE1 and FOXM1 leads to
phosphorylation of FOXM1 in a HGSC cell precursor model [fallopian tube epithelial (FTE)
cells] at residue threonine 600, contributing to activation of FOXM1. Our studies reveal
that the reaction is mediated primarily through the CCNE1 and cyclin dependent kinase
(CDK) 2 complex. Importantly, transformation assays revealed that CCNE1 and FOXM1
contribute to FTE cell proliferation, migration, and invasion in a cooperative manner.
Further evidence for a functional interaction between CCNE1 and FOXM1 was
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observed in HGSC lines. Phosphorylated FOXM1 (p-FOXM1) was found in HGSC cell
lines and primary epithelial ovarian carcinoma (EOC) tumor samples. In primary EOC
tumor samples, CCNE1, FOXM1, and CDK2 correlate strongly with p-FOXM1 expression.
Treatment with a CDK2 inhibitor, dinaciclib, resulted in a marked decrease of p-FOXM1 in
a FTE and HGSC model, validating CDK2 as a critical factor in FOXM1 phosphorylation.
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CHAPTER 1: INTRODUCTION
HUMAN OVARIAN CANCER
Overview of ovarian cancer
Ovarian cancer has been termed a “silent killer” of women, as it is the most lethal
cancer of the female reproductive system and often occurs without definitive symptoms.
The National Cancer Institute (NCI) estimates that there will be 21,750 new ovarian
cancer cases in 2020, accounting for 1.2% of all new cancer cases in the United States
(1). While ovarian cancer may not rank high in terms of prevalence, it is decidedly lethal.
Ovarian cancer is projected to claim the lives of 13,940 women this year, making it the
fifth leading cancer related cause of death for women (1).
The overall 5 year survival rate for women diagnosed with ovarian cancer is
48.6%, but when parsed out to localized versus metastatic disease, the 5 year survival
rate tells a startling story (1). If the cancer remains localized to the ovaries, the 5 year
survival rate is over 90%. Alternatively, if the disease has spread beyond the ovaries, the
5 year survival rate drops drastically, to less than 30%. The majority of ovarian cancer
patients (over 60%) are diagnosed after cancer cells have metastasized; thus many
ovarian cancer patients find themselves facing a dismal survival rate (2). These statistics
underscore the need for more effective early screening and emphasize the difficulty of
successful treatment of advanced stage disease.
Ovarian cancer is a generic term for a heterogeneous set of neoplasms that
localize to the ovaries. Based on the cell of origin, ovarian cancer is classified into three
major categories: epithelial, germ cell, and stromal cell derived tumors. Of these types,
epithelial ovarian cancer (EOC) is the predominant in terms of prevalence, accounting
for around 90% of ovarian cancers (3). Furthermore, EOC can be sub-categorized based
on histology, utilizing a system devised by the World Health Organization (WHO) (4, 5).
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There are five histological EOC subtypes: high-grade serous, endometrioid, mucinous,
clear-cell, and low-grade serous (Figure 1). These subtypes differ in their tissue of origin,
pathogenesis, molecular alterations, risk factors, and overall prognosis. High-grade
serous ovarian cancer (HGSC) is by far the most common subtype, comprising 70% of
EOC (7, 8).
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Figure 1. Epithelial ovarian cancer (EOC) histological subtypes. The upper sections
display the postulated tissues of origin for the EOC histological categories. The lower
sections display H&E staining of the histological subtypes. Reprinted from (6).
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EOC diagnosis
The five-year survival rate for EOC is quite high, above 90%, when detected
early. Unfortunately, only about 15% of EOC cases are diagnosed before the disease
advances, which means the cancer is often not detected until the later stages where the
five-year survival rate decreases dramatically (9). A myriad of issues can factor into
limiting early detection, including nonspecific symptoms, lack of dependable biomarkers,
and ineffective imaging modalities. Nonspecific symptoms include abdominal pain,
swelling, or other nonspecific gastrointestinal issues. These symptoms often persist for
more than 6 months prior to an EOC diagnosis (10). Upon presentation of these
symptoms, a pelvic exam is often performed. However, due to the diminutive size and
internal placement of the ovaries, a pelvic exam is often not sensitive enough to detect
ovarian cancer (10, 11).
Other testing that is commonly performed on patients with suspected ovarian
cancer includes laboratory testing such as measurement of serum carbohydrate antigen
125 (CA125) levels (10). CA125, also known as MUC16, is a heavily glycosylated
transmembrane cell surface protein that is expressed by epithelial ovarian carcinomas,
as well as some normal human tissues (e.g. endometrium, lung, and cornea) (12). The
high molecular weight protein (5MDa) is cleaved and released into bodily fluids, such as
serum. Thus, it is detectable by noninvasive procedures, such as immunoassays, and is
found in 90% of patients with stage III-IV EOC and 50-60% of patients with early stage
EOC (13). Because CA125 levels are not high in patients with early stage EOC and is
also frequently elevated in the context of benign gynecologic conditions, such as
endometriosis, uterine fibroids, pelvic inflammatory disease, and normal menstruation, it
alone is not sensitive nor specific enough for early detection. Even so, CA125 is
currently the most commonly used biomarker for OC. Similar results (the lack of
sensitivity and specificity) have been shown with the usage of various imaging
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modalities, such as transvaginal sonography (TVS), to diagnose EOC. It has recently
been posited that two stage strategies, consisting of some combination of CA125
measurements and TVS, can reduce EOC mortality by providing increased sensitivity
and specificity of detection (14). Another protein, human epididymal secretory protein E4
(HE4), has recently shown promise as an EOC biomarker. In normal tissue, HE4 is
usually weakly expressed in the epithelium of the respiratory and reproductive tracts.
However, HE4 is commonly upregulated in EOC and is similar to CA125, in that HE4 is
overexpressed and secreted from ovarian carcinomas in a small glycosylated form (15).
Thus, HE4 can also be detected in the serum of those with EOC. However, in contrast to
CA125, HE4 has proven itself to be more specific than CA125; HE4 tends to be
overexpressed in only serous and endometrioid tumors (15). The measurement of HE4
and CA125 together has been shown to be an efficient tool to diagnose OC, and may be
used in conjunction with a Symptom Index or algorithms to increase the accuracy of
EOC diagnosis (16, 17).

EOC stage and grade
After a diagnosis of EOC, the cancer is clinically staged. Staging is done
according to the International Federation of Obstetricians and Gynecologists (FIGO),
which includes Stages I-IV (7). Stage I is defined as tumors limited to the ovaries and
peritoneal fluid/washings (7). Stage II is defined as metastasis from the primary tumor
site to pelvic organs, as well as tumors that have extended directly to adjacent organs
without evidence of formal metastasis (7). Stage III is defined as tumors that have
spread from the primary site to the pelvic and abdominal peritoneal surfaces, which can
involve the omentum (most common), small and large bowel surfaces, mesentery,
paracolic gutters, diaphragm, and liver and spleen peritoneal surfaces (7). Stage IV is
defined as distant metastasis from the primary tumor site; including parenchymal liver
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and splenic metastases as well as extra-abdominal metastases (7).
In addition to the staging of ovarian cancer, the FIGO system also classifies the
cancer into grades to indicate the degree of tumor cell differentiation (18). Grade 1
cancer cells are fully differentiated and similar to normal ovarian tissue, Grade 2 is
moderately differentiated tumors, and Grade 3 cancer cells are either poorly
differentiated or completely undifferentiated (18). In the context of serous histology OC,
low-grade serous ovarian cancer is defined as grade 1, whereas high-grade serous is
defined as grade 2 or 3 (19).

EOC prognosis
Poor early detection methods mean that most ovarian carcinomas are diagnosed
at an advanced stage. Prognosis of ovarian cancer is strongly linked with the stage at
diagnosis; the higher the stage, the poorer the prognosis (10). The grade of the cancer is
also associated with prognosis, and especially with predicting disease recurrence (10).
Other poor prognostic factors include: age older than 65 years, advanced stage with
extensive disease, large residual tumor volume after primary surgery, clear cell or
mucinous tumor histology, lower quality of life score, and poor cellular differentiation
(10). Currently, inadequate early detection methods in conjunction with a lack of durable
cures for advanced stage disease account for the poor prognosis of many ovarian
cancer patients.

EOC treatment
The standard of care for ovarian cancer is cytoreductive surgery followed by
combination chemotherapy (10). Conventional chemotherapy post-tumor debulking
surgery consists of six cycles of carboplatin + paclitaxel chemotherapy (20). Paclitaxel is
a taxane that works by inhibiting cell division. It does so by binding to microtubules and
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stabilizing them, thus interfering with spindle formation in prophase and preventing
proper mitotic progression (20). Carboplatin is a platinum agent that alkylates DNA. It
creates adducts within the DNA strands, resulting in DNA crosslinking and inhibition of
DNA replication and mitosis (20). The DNA damage caused by carboplatin treatment
elicits a DNA damage response, and, when the damage is too great to be effectively
repaired, cell death may result. The generally increased proliferative rate of cancer cells
accounts for much of the anti-cancer activity of this agent.

Risk factors and protective factors for EOC
Several deleterious genetic mutations are associated with an increased risk of
EOC. Most hereditary ovarian cancers are resultant from mutations within the BRCA1
and BRCA2 genes, which impair the homologous recombination (HR) DNA repair
pathway. BRCA1 mutation confers a mean cumulative risk for OC by age 70 of 40%,
while BRCA2 mutation confers a mean cumulative risk of 18% for OC by age 70 (21).
Lynch syndrome, which is caused by mutations in the MLH1 and MSH2 DNA mismatch
repair genes, also elevates the risk of ovarian cancer (22).
There are lifestyle factors that are non-genetic that are protective against ovarian
cancer. Pregnancy, breastfeeding, and contraceptive pill usage all significantly reduce
the risk of ovarian cancer (23, 24). Surgical interventions that also reduce the risk of
EOC are bilateral tubal ligation and bilateral salpingo-oophorectomy (25). These
surgical interventions are commonly used as prophylactic treatments in patients with
high-risk of hereditary EOC.
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HIGH-GRADE SEROUS OVARIAN CANCER
The cell origins of high-grade serous ovarian cancer
Since the primary site of ovarian cancer, when diagnosed, is the ovary itself, up
until recently it was thought that the ovarian surface epithelium (OSE) was where the
majority of the HGSC originated from. This hypothesis was also formulated was based
on the incessant ovulation hypothesis, which centers around the fact that the human
female ovulates monthly, and this process involves the rupturing and subsequent repair
of the OSE (26). The constant damage and repair were thought to foster an environment
that is primed for oncogenic transformation. Further support for this hypothesis comes
from epidemiological studies that showed a relationship between the number of
ovulations and the probability of a woman developing ovarian cancer, and additional
factors such as multiparity and contraceptive use confer a large protective benefit, (23,
24, 25, 26).
However, more recent data suggest that the majority of HGSC may originate in
the fallopian tube epithelium (FTE). The initial study that supported this idea examined
fallopian tubal segments that were removed from BRCA mutation carriers undergoing a
prophylactic bilateral salpingo-oophorectomy (24). In 12 specimens examined, six had
regions of cellular dysplasia in the fallopian tubal epithelium, and five had hyperplastic
lesions (27). Upon further examination, these dysplastic and hyperplastic lesions
histologically resembled HGSC, without the oncogenic characteristic of invasion (27).
This suggested that HGSC may originate from the FTE, rather than from the ovary itself.
Additional substantiation for this hypothesis came from gene expression and DNA
methylome analysis that showed that HGSC is more similar to FTE than it is to the OSE
(28, 29). In the current model of the FTE origination of HGSC, p53 signatures [or early
serous proliferations (ESPs)] are the earliest precursor lesions. These lesions, which are
believed to emanate from secretory cells, are characterized by p53 mutations, DNA
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damage, and robust nuclear localization of p53 (Figure 2) (30). Further progression
leads to serous tubal intraepithelial carcinomas (STIC lesions). These lesions are
identified by p53 mutations, nuclear atypia, loss of polarity, increased nuclear to
cytoplasmic ratio, and high proliferative activity (31). These lesions can develop into
metastatic carcinomas, developing tumors on the ovary, peritoneal cavity, or on another
location on the fallopian tube (Figure 2).
Further studies utilizing mouse transgenic models also support the fallopian tube
origination theory. In a mouse model where HGSC relevant genes (BRCA1, BRCA2,
Tp53, and PTEN) were targeted to fallopian tube secretory cells, mice developed STIC
lesions, HGSC, and ovarian and peritoneal metastases. These murine tumors mimicked
human HGSC histologically and immunophenotypically, and displayed the genomic
alterations seen in human HGSC (32). Furthermore, in another study, Dicer/PTEN dual
knockout mice show high-grade serous carcinoma development in the fallopian tubes,
which eventually metastasized to the ovaries and abdominal cavity. In the same study,
removal of the ovaries in the mice did not prevent carcinomas from forming, whereas
removal of the fallopian tubes did prevent carcinoma development (33). Finally, it should
be noted that a recent mouse transgenic study demonstrates that both the OSE and the
FTE can be origination points for HGSC (34). Based on the available data, it seems
likely that both the FTE and the OSE play key roles in HGSC, but that OSE originated
tumors are less common. Further research is needed to clarify whether FTE vs. OSE
cell origin reflects two phenotypically distinct classes of HGSC.

10

Figure 2. Model for HGSC oncogenesis from the FTE. Early serous proliferations are
the earliest manifestations of HGSC oncogenesis in the fallopian tube, characterized by
p53 mutations and DNA damage. The ESPs can progress into STIC lesions, which
display more oncogenic characteristics such as nuclear atypia, loss of polarity, and high
proliferative activity. The STIC lesions can develop into metastatic disease, moving to
other sites on the fallopian tube, ovary, or peritoneal cavity. Reprinted from (31).
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Genomic characteristics of HGSC
Genomic instability is a hallmark of HGSC, as shown by TCGA data, with copy
number alterations (CNA) playing the major role (35, 36). One common mutation is in
TP53. TP53 mutations are ubiquitous in HGSC tumors and constitute the earliest
observed gene abnormality in the disease, in “p53 signature lesions” (36, 37). Another
important common class of mutations is in BRCA1/2. The mutations in BRCA1/2 are
significant because they impair the homologous recombination DNA repair (HR) in many
HGSC cases, leading to the accumulation of DNA damage and genomic instability (36).
However, HR impairment alone cannot account for the almost ubiquitous genomic
instability observed in HGSC, as this defect is only observed in about 50% of HGSC
(36). In approximately 20% of HGSC cases, CCNE1 is amplified and is mutually
exclusive with the HR deficiency caused by BRCA1/2 mutations, thus it is a potential
participant in inducing genomic instability in HGSC (38). CCNE1 amplification and its
consequent overexpression can lead to inappropriate progression through the cell cycle
and induce DNA replication stress (39). Another prospective contributor to HGSC
genomic instability is FOXM1. The FOXM1 pathway is activated in 84% of HGSC cases,
which includes both HR proficient and HR deficient tumors (36, 40). FOXM1 is a
consistent biomarker for poor prognosis in solid tumors, marking it as a possible
generator of genomic instability (41, 42). In agreement, we have recently shown that
FOXM1 expression in pan-cancer shows a significant association with genomic
instability (43). Genomic instability is an indispensable key aspect of HGSC as it
contributes to tumor evolution as well as treatment resistance. Because of this, it is
imperative to determine the relevant factors driving genomic instability in HGSC (44, 45).
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HGSC treatment
Treatment of HGSC follows the traditional treatment of EOC outlined above.
Though there is frequently an initial positive response to platinum + taxane front-line
chemotherapy in HGSC patients, around 75% of patients with advanced disease will
ultimately relapse, typically within 18 months. These disease-recurrent patients are then
candidates for treatment with various second-line chemotherapies (20, 46).
Importantly, HR deficiency in HGSC tumors has recently been developed as a
novel treatment target. Poly ADP ribose polymerase (PARP) inhibitors have been
introduced as an effective therapy for HR deficient HGSC. PARP is an enzyme involved
in base excision repair (BER) of DNA (47). The PARP inhibitors work by blocking the
release of the PARP molecule from the DNA strand, inhibiting BER. Later collision of
PARP protein adducts with the DNA replication machinery leads to double strand
breaks, which requires HR for error-free repair. Thus, this makes PARP inhibitors an
attractive therapy for treating BRCA1/2 mutated HGSC, as HR is compromised in these
tumors. HR deficiency leads to reliance on other more deleterious DNA repair pathways,
such as nonhomologous end-joining (NHEJ), causing an accumulation of DNA damage
and subsequent cell death (47). This is known as synthetic lethality, which occurs
between two genes when a mutation/loss of either gene alone retains a viable
phenotype, but a mutation/loss of both genes leads to cell death (48). In this case, HR
deficiency (e.g. due to BRCA mutation) is synthetically lethal with PARPi treatment.
Clinical trials have shown selective toxicity of the PARP inhibitors towards BRCA1/2
mutated tumors (49, 50, 51). Consequently, the PARP inhibitor olaparib was FDA
approved for treatment of BRCA-mutated ovarian cancers in 2014 (52, 53). It has been
found, however, that not all patients that are treated with PARP inhibitors respond, and
those that do respond typically develop resistance (54, 55, 56, 57). This shows that
investigating methods to overcome PARP inhibitor resistance in BRCA mutant HGSC,
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and identifying means to better target HR competent tumors with PARPi, is of great
importance.

FOXM1
FOXM1 structure, expression, and regulation
The discovery of FOXM1 occurred during a cDNA screen, where it was initially
dubbed M-phase phosphoprotein 2 (MPP-2), as it was identified as a protein
phosphorylated during the M phase of the cell cycle (58). Other original terms used to
refer to FOXM1 include Trident (murine), WIN or INS-1 (rat), MPP-2 (human c-DNA),
and HFH-11. Further research into FOXM1 determined that it had similar molecular
features to the Forkhead box (FOX) family of transcription factors. The FOX transcription
factor family, which has approximately 50 members in humans, is unified by a conserved
winged helix DNA binding domain, and FOXM1 shares a sequence motif in this region
with other members of the FOX family (59, 60).
FOXM1 is characterized by a DNA binding domain, a transactivation domain
(TAD) (located at the C terminus), and an N terminal repressor domain (NRD). The TAD
is crucial for activating expression of target genes and the NRD can repress the TAD by
interacting directly with it (61, 62). The human locus of FOXM1 is on chromosome
12p13.33 and includes 10 exons (9 are coding), with alternative splicing giving rise to
four different FOXM1 isoforms: FOXM1a, FOXM1b, FOXM1c, and FOXM1d. These
splice variants are achieved by alternative splicing of exons Va and VIIa. FOXM1a
contains both exons Va and VIIA, FOXM1b contains neither exon, FOXM1c contains Va,
and FOXM1d contains VIIa (Figure 3). FOXM1a appears to be transcriptionally inactive,
whereas FOXM1b, FOXM1c, and FOXM1d act as transcriptional activators (43, 58, 63).
It was previously thought that FOXM1a was inactive due to the presence of VIIa in the
transactivation domain, however FOXM1d also contains VIIa and has been identified as
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promoting the epithelial-mesenchymal transition by activating a protein called ROCKS in
colorectal cancer (63). In normal tissues, HGSC cell lines, and pan-cancer, FOXM1c is
the most highly expressed FOXM1 isoform, while FOXM1b shows moderate expression
and FOXM1a shows the lowest expression (40, 43).
FOXM1 mRNA and protein are expressed in a cell cycle dependent manner,
upregulated during S phase and expression peaking at the G2/M boundary (58).
Similarly, FOXM1 activity follows a cell cycle dependent pattern. FOXM1 activation is
mediated primarily through phosphorylation by various kinases, and the transcriptional
activity of FOXM1 is influenced by its phosphorylation state. Phosphorylation of FOXM1,
and thus activation of FOXM1, begins in late G1 and sequential phosphorylations occur
as the cell cycle progresses, generating the hyperphosphorylated and fully active form of
FOXM1 by the G2/M boundary (62). One phosphorylation reaction of note is the
phosphorylation of FOXM1 at residues S331 and S704 by the Raf/MEK/MAPK pathway,
upon which FOXM1 is subsequently shuttled from the cytoplasm into the nucleus, where
further phosphorylation and activation can occur (62, 64).
FOXM1c is the most highly expressed FOXM1 isoform in HGSC and has its own
unique pattern of phosphorylation sites. It contains the residues needed for the above
phosphorylation by the Raf/MEK/MAPK pathway, as well as CDK1/2 phosphorylation
sites (Figure 4). In conjunction with a partner cyclin (cyclin A or cyclin E1), CDK1/2
phosphorylate FOXM1c at residues 600, 611, and 672 during G2 phase, which relieves
repression of the TAD by the NRD (64, 65, 66).
Additional regulation of FOXM1 is achieved through micro RNAs (miRNAs).
Many studies have been done on various miRNAs with the capability to modulate
FOXM1 expression. miRNA are small, non-coding RNA molecules that can bind to target
mRNAs via complementary base-pairing. This prevents translation of the mRNA by
various means: destabilization of the mRNA, cleavage of the mRNA, or the inability to be
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translated by the ribosome due to being bound by the miRNA. One miRNA that has
been studied extensively in regard to FOXM1 regulation is miRNA-149. By targeting and
binding to FOXM1, miRNA-149 has been shown to inhibit growth, migration, and
invasion of colorectal cancer cells and to reverse resistance to 5-fluorouracil, a
chemotherapy agent (67, 68). In another type of cancer, non-small-cell lung cancer,
miRNA-149 was shown to prevent the epithelial-to-mesenchymal transition promoted by
FOXM1 (69).
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Figure 3. Genomic structure and isoforms of FOXM1. The gene region of FOXM1 is
transcribed into precursor mRNA. The precursor mRNA has a 5’ untranslated region
(UTR) and a 3’ UTR, with 9 introns and 10 exons. Va and VIIa are two alternative exons.
The mRNA undergoes alternative splicing to remove the introns and give rise to the
different isoforms of FOXM1. All splice variants contain a nuclear repression domain
(NRD), DNA binding domain (DBD), and transactivation domain (TAD). FOXM1a
contains both exons Va and VIIA, FOXM1b contains neither exon, FOXM1c contains Va,
and FOXM1d contains VIIa. Reprinted from (62, used under a Creative Commons
Attribution 4.0 International license:
https://creativecommons.org/licenses/by/4.0/legalcode)

17

Figure 4. FOXM1c protein diagram. FOXM1c is comprised of eight exons, denoted by
the roman numerals (II-VIII); in contrast to other isoforms, it contains only alternative
exon Va. The N terminus is followed by a DNA binding domain (DBD). The
transactivation domain (TAD) is near the C terminus. ERK1/2 phosphorylates FOXM1c
at residues 331 and 704, and CDK 1 and 2 phosphorylate FOXM1c at residues 600,
611, and 672. Reprinted from (64).
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FOXM1 function
FOXM1 is a transcription factor crucial for cell cycle progression, particularly
through the G1/S and G2/M checkpoints, and for mitotic progression (70). Exemplifying
this, studies showed FOXM1 knockout MEFs proliferated slowly, did not enter mitosis
correctly, accumulated mitotic defects, and eventually went into cellular senescence (71,
72). More in depth examination into the mechanisms that FOXM1 may be involved with
revealed that FOXM1 is important for appropriate chromosomal segregation, as loss of
FOXM1 caused genomic instability including the accumulation of polyploid cells (73, 74).
Furthermore, the transcriptional targets of FOXM1 are involved with mitotic progression,
proper assembly of mitotic spindles, proper chromosome segregation, and cytokinesis
(75, 76). In summary, cell cycle regulation is the canonical function regulated by FOXM1
transcriptional activity (59, 77). Additionally, FOXM1 has a role in DNA repair, cell
migration, stemness, and chemoresistance (78, 79, 80). FOXM1 does this by
upregulating the expression of genes involved in these processes.

FOXM1 and cancer
FOXM1 is both overexpressed and functionally activated in many human cancers
and has been found to have oncogenic activity both in vitro and in vivo (77, 43). The
processes underlying FOXM1 overexpression in cancer are many and include genomic
amplification (40, 43), p53 mutation (81, 82), Rb loss of function (40), FOXO3 loss (83,
84), and Myc, HIF-1, SP1, STAT3, Gli1, and E2F activation (85, 86, 87, 88, 89, 90).
FOXM1 activation is achieved through phosphorylation by mitogenic kinases and
cyclin/CDK complexes, which are frequently dysregulated in cancer. Through its role as
a transcription factor, FOXM1 stimulates oncogenic phenotypes and induces
progression through the G2/M checkpoint (77). Overexpression and improper activation
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of FOXM1 can contribute to an oncogenic phenotype by spurring cells through the cell
cycle inappropriately, leading to increased cellular proliferation.
Two of the hallmarks of cancer are deregulation of the cell cycle and uncontrolled
cellular proliferation; deregulation of the cell cycle and subsequent uncontrolled
proliferation are the most common oncogenic phenotypes associated with FOXM1. In
both spontaneous and genetically engineered animal models of cancer, ectopic
expression of FOXM1 leads to larger tumors and quicker tumor formation (91).
Beyond cell cycle regulation, additional oncogenic roles that FOXM1 is
associated with include cancer cell stemness, chemoresistance, genomic instability, and
DNA replication stress (80, 91, 92). Of particular note, a study showed that
downregulation of FOXM1 reduced the expression of invasion related proteins matrix
metalloproteinase-2, matrix metalloproteinase-9, and vascular endothelial growth factor,
which are proteins involved in invasion and angiogenesis. This downregulation of
FOXM1 also inhibited cell growth and decreased both migration and invasion of
pancreatic cancer cells (79).

CCNE1
CCNE1 structure, expression, and regulation
CCNE1 was discovered in 1991, via a screen of human cDNAs that
compensated for the loss of yeast interphase cyclins (93). Cyclins are a class of proteins
that each have its own unique protein/expression degradation profiles that correspond to
specific phases of the cell cycle. Functionally, cyclins bind to cyclin dependent kinases
(CDKs) to phosphorylate and coordinate specific events related to the cell cycle position
(94). CCNE1 is located on chromosome 19.q12 and is 12,415 base pairs long (95).
There are nine protein splice variants, with CCNE1-like isoform 1 (E1L) considered the
canonical major form that complexes with CDKs (96). The major form, E1L, is comprised
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of 410 amino acids and has two domains made up of five alpha helices each (97)
(Figure 5). The protein contains both a nuclear and centrosome localization sequence,
along with a conserved cyclin box (98).
The protein expression of CCNE1 increases through G1, peaks at the G1/S
boundary, and is degraded in S phase (99). In the cell, it is located in both the cytoplasm
and the nucleus, though it is primarily nuclear (100). Transcriptional regulation of CCNE1
occurs through phosphorylation of the Rb/E2F complex by the cyclin D (CCND) and
CDK4/6 complex. Rb phosphorylation leads to the dissociation of E2F1-3 from Rb and
allows E2F to bind to E2F binding sites within the CCNE1 promoter, promoting
transcription of CCNE1. The newly made CCNE1 protein then continues to promote the
phosphorylation of the Rb/E2F complex, allowing further activation of E2F and
upregulation of CCNE1 in a positive feedback loop (101). Another common mechanism
of CCNE1 transcriptional regulation is through C-Myc, which upregulates CCND1,
causing increased phosphorylation of the Rb/E2F complex and E2F activation (102). In
contrast, negative regulation of CCNE1 is achieved through repression by E2F4-6, which
recruit factors such as histone deacetylases, methylation complexes SUV39H1 and
HP1, and nucleosome remodeling complexes to decrease CCNE1 transcription during S
phase, after CCNE1’s function to activate proteins involved in the progression through
the G1/S boundary has been completed (98).
CCNE1 is also regulated post-transcriptionally through microRNA mediated
inhibition of CCNE1 synthesis, inhibition by p21 and p27 (which block CDK binding to
the cyclin subunit), and through ubiquitin mediated degradation (through both the Cul3
and SCFFbw7 pathways) (98).

CCNE1 function
Cyclins bind with a CDK subunit, upon which a conformational change in the
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CDK occurs that opens up the active site and the ATP binding pocket. Both inhibitory
and activating phosphates are modulated; the complex is not able to fulfill its activity until
the inhibitory phosphate has been removed by a phosphatase.
CDK2 is the major CDK binding partner of CCNE1, as it binds with the highest
affinity. CCNE1 binds to CDK2 primarily through the C-(PSTAIR) helix and the activation
segment of CDK2 (97) (Figure 5). The activation segment of CDK2 is crucial for protein
substrate recognition (97). CCNE1 can also bind CDK1 and CDK3, with CDK1 able to
promote the G1/S transition in CDK2 null MEFs (103).
CCNE1 has a myriad of functions, some CDK dependent and some CDK
independent. A major CDK dependent function of CCNE1 is mediating G1/S transition.
One of the major ways this is accomplished is through phosphorylation of Rb by the
CCNE1/CDK complex. The complex phosphorylates Rb, releasing E2F proteins and
promoting transcription of critical genes that promote S phase initiation and progression
(98).
Some of the other CDK2 dependent functions of CCNE1 are centrosome
duplication, histone gene transcription, DNA synthesis, and DNA repair (98). The CDK
independent functions of CCNE1 involves also centrosome duplication as well as preinitiation complex formation (98). For the latter, CCNE1 is loaded onto chromatin during
the G0 into S phase progression and facilitates the minichromosome maintenance
complex component 2 (MCM2) loading onto chromatin through interactions with the
MCM2 and chromatin licensing and DNA replication factor 1 (CDT1). These activities
help promote pre-initiation complex formation prior to centrosome duplication (98, 104).
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Figure 5. Crystal structure of CCNE1 complexed with p-CDK2. CCNE1 is comprised
of two domains made up of five alpha helices each. CDK2 contains both alpha helices
and beta sheets. The activation segment of CDK2 is crucial for protein substrate
recognition. Reprinted from (97).
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CCNE1 and cancer
CCNE1 is frequently overexpressed in cancer, and one mechanism of this is
through CCNE1 gene amplification. For example, CCNE1 is amplified in 20% of HGSC
cases (36). However, increased expression of CCNE1 in HGSC is not only due to
genomic amplification, as the number of CCNE1 overexpressing HGSC cases is twice
as high as CCNE1 amplified cases, suggesting other methods of CCNE1
overexpression (105).
A potential contributor to oncogenesis may be the increased expression of low
molecular weight (LMW) cyclin E1 protein isoforms. CCNE1 exists in nine isoforms,
however five of these are seen only in cancer (106). The cyclin E-like isoforms (EL), EL2, 3, 5, and 6, are generated by proteolysis at two proteolytic sensitive domains in
CCNE1, and the fifth isoform originates from an alternative translation site. All of these
isoforms are low molecular weight, ranging from 34-49 kDa, whereas the EL-1, the
canonical major form, is ~50 kDa (Figure 7) (96). These LMW forms have a higher
affinity for CDK2 , thus they are more biologically active and phosphorylate substrates
more readily (96,105).
Other mechanisms leading to the increased expression of CCNE1 observed in
cancer is homozygous deletion of Rb (leading to constitutive activity of E2F and
subsequent transcription of CCNE1), MYC amplification (also leading to increased
transcription of CCNE1), or a mutation in SCFFbw7 (leading to decreased degradation of
cyclin E1through a ubiquitin mediated pathway) (105).
The results of cyclin E1 overexpression in cancer are improper DNA replication
initiation, replication stress, and inappropriate centrosome duplication, ultimately leading
to the accumulation of mutations that promote oncogenesis (107, 108).
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CCNE1 and HGSC
Analysis of TCGA data for 22 different cancer types revealed that CCNE1
is commonly amplified in gynecological cancers, gastrointestinal cancers, and lung
cancers (38). Importantly, CCNE1 was the most commonly amplified gene in HGSC
(38). Cyclin E1 expression is associated with the beginning stages of HGSC
development; STIC lesions have increased CCNE1 copy number gain/amplification and
have increased expression of cyclin E1 by IHC (Figure 6). Ectopic expression of CCNE1
in FTE cells, the presumed HGSC precursor cells, promoted hallmarks of transformation,
including cell proliferation, anchorage independent growth, and loss of contact inhibition
(39).
Knockdown of CCNE1 in CCNE1 amplified ovarian cancer cells led to significant
growth inhibition and increased apoptosis, in comparison to cancer types that had low
CCNE1 levels, and ectopic expression of cyclin E1 increased proliferation in the cancer
cell lines with low basal cyclin E1 expression (109). These data support that cyclin E1
plays a crucial role in mediating oncogenic HGSC phenotypes.
As noted before, germline BRCA1/2 mutations are the predominant genetic risk
factor for HGSC, and so a closer look into the role that CCNE1 and BRCA1/2 disruptions
may play together in HGSC oncogenesis is needed. Using data from a genome-wide
shRNA synthetic lethal screen, a study showed that BRCA1 and members of the ubiquitin
pathway are selectively required in cancers that harbor CCNE1 amplification. As such,
CCNE1 amplification was found to be mutually exclusive with BRCA1/2 mutations (38).
Mechanistically, CCNE1 amplified tumors have increased DNA damage, which requires
an effective homologous recombination repair pathway for resolution. Therefore,
BRCA1/2 mutations and CCNE1 amplifications are not harbored together in HGSC as it
would be synthetically lethal. Interestingly, this may mean that one of the typical
chemotherapies used in HGSC treatment, carboplatin, may not be as effective in tumors
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with CCNE1 amplifications, as such tumors are not HR deficient and thus can effectively
repair double strand DNA breaks caused by drug treatment (38).
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Figure 6. Cyclin E1 expression in HGSC precursor lesions. A cartoon illustrating the
progression of HGSC from normal FTE is shown at the top. p53 signatures arise first,
followed by the development of STIC lesions. These lesions progress even further into
invasive serous carcinomas. The lower portion of the figure shows H&E and IHC staining
of a p53 signature and a STIC lesion. The top row shows the staining of the p53
signature, with high level staining of mutant p53 and lower levels of Ki-67 and Cyclin E1
staining. The lower two rows represent a STIC lesion, showing staining for mutant p53,
Ki-67, and CCNE1. Reprinted from (39).
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The potential for FOXM1 and CCNE1 cooperativity in HGSC
FOXM1 and CCNE1 each contribute to HGSC as well as other cancers. Since
FOXM1 contains residues that are known to be phosphorylated by CDK complexes, it may
be that the CCNE1/CDK complex has a role in a phosphorylation event that activates
FOXM1. A study published in 2006 provided evidence for a CCNE1/CDK2 interaction with
FOXM1, showing that CCNE1/CDK2 enhanced FOXM1 transcription in a reporter gene
assay, and that three amino acid residues within the FOXM1 protein are CCNE1/CDK2
phosphorylation sites (65). Also of note, our prior analysis of TCGA data indicates that
FOXM1 and CCNE1 mRNA and protein expressions are strongly correlated (43).
Moreover, we have shown that ectopic expression of CCNE1 increases FOXM1
expression in FTE cells (43). CCNE1 enhances FOXM1 transcriptional activity and
CCNE1/FOXM1 co-expression also promotes genomic instability (92, 43). All of these
data suggest that CCNE1 and FOXM1 may cooperate in HGSC, potentially in part through
activation of FOXM1 by phosphorylation by CCNE1/CDK complexes. To address these
important questions, we wanted to determine the impact that the CCNE1/CDK complexes
have on FOXM1 phosphorylation status in FTE cells and HGSC, as well as investigate the
effect that CCNE1 and FOXM1 together have on FTE cellular transformation phenotypes.
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CHAPTER 2: MATERIALS AND METHODS

Human tissues
Bulk normal ovary (NO) tissues and EOC samples (n=42) were obtained from
patients undergoing surgical resection at Roswell Park Comprehensive Cancer Center
(RPCCC) under Institutional Review Board-approved protocols, as described previously
(119). Flash-frozen bulk tumor tissue samples were crushed using liquid nitrogen prechilled mortar and pestles. Total protein was extracted using radioimmunoprecipitation
assay (RIPA) buffer (25 mM Tris HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS)) containing Protease Inhibitor Cocktail
(SIGMA), Phosphatase Inhibitor Cocktail 1 (SIGMA) and Phosphatase Inhibitor Cocktail 2
(SIGMA). Upon the addition of RIPA buffer, the frozen tissue powder was immediately
homogenized using an electric homogenizer with disposable microtube pestles. The
solution was further sonicated with a Bioruptor (Diagenode).

Cell lines
COV362 and COV318 cell lines (Sigma) were cultured in DMEM (Corning)
supplemented with 10% fetal bovine serum (FBS, Invitrogen), 2 mM glutamine (Life
Technologies), 1% penicillin-streptomycin (pen-strep, Life Technologies). KURAMOCHI
and OVSAHO (Japanese Collection of Research Bioresources Cell Bank) and SNU-119
(Korean Cell Line Bank) cell lines were cultured in RPMI-1640 (Hyclone) supplemented
with 10% FBS and 1% pen-strep. OVCAR3 cells (American Type Tissue Culture
Collection) were cultured in DMEM with 10% FBS and 1% pen-strep. Caov3 and OVCAR5
cells were a generous gift from Professor Anirban Mitra (Indiana University) and were
cultured in DMEM with 10% FBS and 1% pen-strep. OVCAR8 cells (National Cancer
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Institute Division of Cancer Treatment and Diagnosis Cell Line Repository) were cultured
in DMEM (Corning) supplemented with 10% FBS and 1% pen-strep, Life Technologies.
Fallopian tube epithelial (FTE) cells immortalized with hTERT and mutant Tp53 (FT282
cells) were a generous gift from Professor Ronny Drapkin (University of Pennsylvania)
and were cultured in DMEM-Ham’s F12 50/50 (Corning) supplemented with 10% FBS and
1% pen-strep (Figure 7). Clonal FT282 cells (FT282-C11) cells were generated as
described previously (112). All cell lines were maintained at 37°C in a humidified incubator
with 5% CO2. Cell culture medium was changed every 3-5 days depending on cell density.
For routine passage, cells were split at a ratio of 1:4-10 when they reached 85% to 90%
confluence. Cell lines were authenticated by short tandem repeat (STR) analysis at the
DNA Services Facility, University of Illinois at Chicago, and tested for mycoplasma, and
confirmed to be mycoplasma free, by RT-qPCR at the Epigenomics Core Facility,
University of Nebraska Medical Center.
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Figure 7. Generation of an immortalized fallopian tube epithelial cell line (FT282).
FTE cells were removed from the lining of the fallopian tube. Fallopian tube secretory cells
(FTSEC) are able to grow on plastic whereas ciliated cells cannot. FTSEC were
immortalized by transduction with lentivirus expressing mutant p53 and retrovirus
expressing h-TERT. Cells surviving antibiotic selection are immortalized but nontransformed. Reprinted from (111).
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Generation of FT282-CCNE1, FT282-FOXM1c, and FT282-CCNE1 + FOXM1c ectopic
expression cell lines
pCW57-MCS1-2A-MCS2 (Addgene #71782) was generated by converting
pCW57.1 (Addgene #41393) from Gateway cloning to sticky end cloning by adding a
multiple cloning site. pCW57-CCNE1 (RefSeq NM_001322262) was generated by PCR
subcloning CCNE1 (Harvard PlasmID Repository, HSCD00326535, RefSeq
NM_001322261) into pCW57-MCS1-2A-MCS2. The tetracycline-inducible lentiviral
pCW57.1-DDK-FOXM1c vector was generated by subcloning human FOXM1c from
pCMV6 (Origene: SC112825) into –AN-DDK plasmids (Origene: PS100014), then
subcloning into the pCW57.1 (Addgene: 41393) with Gateway cloning (Life
Technologies).
Replication-deficient lentivirus was produced by transient transfection of 6.0 μg
psPAX2 (Addgene #12260), 2.0 μg pMD2.G (Addgene #12259), and 8.0 μg transfer
plasmid into HEK293T (293T) cells in a 10 cm dish with Lipofectamine 2000 reagent
(Life Technologies, Carlsbad, CA, USA), according to the manufacturer’s instructions.
Viral supernatants were collected at 48 h and passed through a 0.2 μm filter. Functional
titration was performed by transduction of 293T cells with serially diluted virus in the
presence of polybrene (4 μg/mL, Sigma) for 6 h followed by puromycin (Life
Technologies) selection 48 h post-infection. After selection, cells were allowed to recover
and were expanded.
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Table 1. FTE cell lines used in this study. Note: all FT282 cells lines are from clonal
derivative (FT282-C11) reported previously (112).
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Pharmacological Inhibitors and cellular treatments
Cells were treated with CDK inhibitors (CDKi) dinaciclib (ab219469, solubilized in
DMSO) from Abcam, R03306 (solubilized in DMSO), palbociclib (solubilized in DMSO),
AT7519 (solubilized in DMSO) from Selleck. 1 µg/mL of doxycycline (dox) was added to
the media of FT282 cell lines 24 hours post seeding, and CDKi was added 24 hours postdox treatment. 24 hours after the addition of CDKi, cells were harvested and total cellular
proteins were extracted. In other experiments, OVCAR8 cells were treated with CDKi 24
hours post-seeding and, 24 hours later, nuclear and cytoplasmic proteins were extracted.

Protein extractions and Western blot analyses
Whole cell protein extracts were prepared using RIPA buffer [1X PBS, 1% NP40,
0.5% sodium deoxycholate, 0.1% SDS] supplemented with protease and phosphatase
inhibitors (Sigma). RIPA extracts were centrifuged at 4°C for 10 minutes at 14000g, and
the supernatant fraction was harvested. Nuclear extracts were prepared using the NEPER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific) supplemented with
protease and phosphatase inhibitors. Protein concentrations were determined using BCA
protein assays (Thermo Scientific). Equal amounts of protein (20-50 µg) were fractionated
on 4-12% gradient SDS-polyacrylamide gel electrophoresis gels (Invitrogen) and
transferred to PVDF membranes (Roche). Membranes were stained with Ponceau S to
confirm efficient transfer and equal loading, and binding of non-specific proteins were
blocked using 5% nonfat dry milk in Tris-buffered saline Tween-20 (TBST) for 1 hour at
room temperature. The membranes were then incubated with primary antibody in 5%
nonfat dry milk in TBST at 4°C overnight followed by incubation with secondary antibody
in 5% nonfat dry milk in TBST for 1 hour at room temperature. Primary and secondary
antibodies information are provided in Table 3. Enhanced chemiluminescence (Pierce

34
ECL Western Blotting Substrate, Thermo Fisher Scientific, catalog no. 32106 and
Supersignal West Pico Plus Chemiluminescent Substrate, Thermo Fisher Scientific,
catalog no. 34580) were used for protein detection, in conjunction with photographic film
developing. Quantification of protein bands on film images were performed using ImageJ
software (Image Processing and Analysis in Java, National Institute of Health).
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Table 2. Primary and secondary antibodies used in this study.
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In vitro clonogenic survival assays
To assess clonogenic survival (a.k.a. colony formation), cells were trypsinized,
counted, and seeded at a density of 500 cells per well in 6-well tissue culture plates. 1
µg/mL dox was added directly to the media 24 hours after seeding and replenished every
48 hours. The plates were incubated for 8 days. Following incubation, cells were fixed
using ice cold 100% methanol, rinsed with PBS, and stained with 0.5% crystal violet for
30 minutes at room temperature. After staining, the cells were rinsed with Millipore filtered
water and air dried overnight. Colonies containing over 50 cells were counted using Image
J software.

Direct cell counting assays
Cells were seeded at a density of 20,000 cells per well into six-well plates, seeding
each cell line in triplicate. A separate plate was seeded for each day of counting. 24 hours
post seeding, medium was replaced with fresh medium containing 1 µg/mL dox and dox
was replenished every 48 hours throughout the experiment. Beginning at 24 hours after
the addition of dox, cells were counted. To count cells, wells were washed with room
temperature PBS, trypsinized, centrifuged at 500g for five minutes, resuspended in one
mL of media, and counted using a Bio Rad automated cell counter, model number TC20.
Cell counting was repeated every 24 hours for 5 days and the experiment was repeated
three times.

Cell invasion and migration assays
Assays were performed using Corning Biocoat Matrigel Invasion Chambers
(control plates catalog no. 354578; invasion plates catalog no. 354480), according to the
manufacturer’s instructions. Briefly, 125,000 cells/mL were suspended into culture
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medium containing 1 µg/mL dox. Medium containing chemoattractant and 1 µg/mL dox
was added to the wells of the plate; the chambers (Biocoat Matrigel chambers for invasion
assays and control inserts for migration assays) were placed into the wells. 0.5 mL of the
cell suspension (approximately 2.5 × 10! cells) was added into the chambers. The plates
were incubated for 22 hours in 37°C in a humidified incubator with 5% CO2. Following
incubation, the media was aspirated from each well and a cotton swab was run across the
surface of the chamber to remove non-invading cells. 100% methanol was added to each
insert for 2 minutes to fix the cells. Then, 0.5% crystal violet was added to each insert and
allowed to sit for 2 minutes. Following this step, the inserts were washed with water to
remove excess stain, air dried overnight, and visualized with a light microscope at 100x
magnification. Five representative images were taken from each insert and cells were
manually counted using ImageJ. Data presented are the average cell numbers from the
five images.

Statistical analyses
Student’s t-test was used to compare differences between means of two groups.
Spearman’s R test was used to measure the strength of association between two
variables. Two-way ANOVA test used to compare the means between two groups that
were split by two independent variables. For all analyses, significance was inferred at P <
0.05 and P values were two-sided. Statistical analyses were performed using GraphPad
Prism (GraphPad Software, Inc).
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CHAPTER 3: RESULTS

Ectopic expression of FOXM1 and CCNE1 induces FOXM1 phosphorylation in
FT282 cells
We hypothesized that cyclin E1 post-translationally activates FOXM1 through
phosphorylation. To test this, we utilized a HGSC precursor cell model, the immortalized
FTE cell line FT282 (Table 1). We engineered clonal FT282 cells (FT282-C11, hereafter
referred to as FT282) (112) for dox-inducible expression of CCNE1, FOXM1c, or both
(E1/F1). Importantly, western blotting revealed that only the FT282 cell line expressing
both CCNE1 and FOXM1c had expression of phosphorylated FOXM1 (i.e. p-FOXM1)
(Figure 8). In this western, we utilized an antibody specific for p-FOXM1 at threonine
600, a cyclin E1/CDK2 phosphorylation site in FOXM1 that was previously identified
(65). To further investigate the kinetics of the phosphorylation of FOXM1, we measured
p-FOXM1 at various time points by Western blot (Figure 9). In the control cell line and
the cell lines overexpressing either CCNE1 or FOXM1, no phosphorylation of FOXM1
was seen, which is consistent with the above results. Induction of FOXM1 was seen
around 4 hours after the addition of dox in the FOXM1 ectopic expression line (Figure
9B) and induction of CCNE1 was seen around two hours after the addition of dox in the
CCNE1 ectopic expression line (Figure 9C). In the dual E1/F1 overexpressing line,
CCNE1 and FOXM1 were induced at about 2 hours post dox and, importantly, p-FOXM1
was present starting at 8 hours post dox-treatment (Figure 9D).
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Figure 8. Phosphorylated FOXM1 is present only in FT282 cells with ectopic
expression of both FOXM1 and CCNE1. Western blot analysis of p-FOXM1, total
FOXM1, and CCNE1 in the FT282 cells engineered for dox-inducible empty vector
control (57), FOXM1 (F1), CCNE1 (E1), or E1/F1 expression, and grown for 24 hours in
the presence of 1 µg/mL dox, along with quantification of the western blot. Left: Western
blot image. Right: Quantification of bands using Image J.
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Figure 9. FOXM1 phosphorylation kinetics in engineered FT282 cells. Western blot
analyses of p-FOXM1, total FOXM1, and CCNE1 in the FT282 cells engineered for dox
inducible empty vector control (57), FOXM1, CCNE1, or E1/F1 expression and grown in
the presence of 1 µg/mL dox. Protein was harvested at different timepoints across a 24hour time period. + denotes the positive control line (E1/F1 line) A. C11 57 (i.e. vector
control) cells, B. C11 57 FOXM1 cells, C. C11 57 CCNE1 cells, and D. C11 57 E1/F1
cells.
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The effect of CDK inhibitors on CCNE1-dependent FOXM1 phosphorylation in
FT282 cells
CCNE1 forms a complex with a cyclin dependent kinase (CDK) and causes a
conformational change within the CDK, opening up the CDK active site and ATP binding
pocket. Once this occurs, the complex is able phosphorylate proteins involved in cell
cycle progression. Cyclin E1 most commonly complexes with CDK2, though it can
complex with other CDKs, including CDK1 (103). To determine which CDK mediates
cyclin E1-dependent phosphorylation of FOXM1, our experimental strategy was to
initially determine the expression of CDK1 and CDK2 in FT282 cell lines, and next to
treat FT282 cell lines with a panel of CDK inhibitors (CDKi) with differing target
specificities (Table 3). We observed CDK1 and CDK2 protein expression in all FT282
cell lines; however, the dual expressing E1/F1 line showed slightly elevated CDK1 and
CDK2 protein expression (Figure 10). FT282-CCNE1 cells also showed elevated
CDK1/2 expression to a lesser extent. These elevations may be related to the
stabilization of cyclin E1/CDK1/2 complexes.
Next, we treated the FT282 E1/F1 cells with dinaciclib, a well-established CDK1,
2, 5, and 9 inhibitor (Table 3). Notably, dinaciclib treatment decreased the amount of pFOXM1, in a dose dependent manner, without substantially affecting the levels of total
FOXM1 or CCNE1 (Figure 11). Next, we tested the effects of R03306, a CDK1 inhibitor.
Unexpectedly, treatment of FT282 E1/F1 cells with R03306 caused an increase in pFOXM1 without significantly impacting the levels of FOXM1, CDK2, CDK1, or CCNE1
(Figure 12). Furthermore, Palbociclib, a CDK4 and 6 inhibitor, treatment did not impact
the levels of p-FOXM1, or of total FOXM1, CDK2, CDK2, or CCNE1 levels (Figure 13).
Finally, treatment of the FT282 E1/F1 cells with AT7519, a CDK 1, 2, 4, 6 and 9 inhibitor,
led to a decrease in p-FOXM1 levels (Figure 14). Taken together, the results of these
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experiments suggest that CDK2 is the chief CDK responsible for CCNE1-mediated
FOXM1 phosphorylation in FT282 cells (Table 3)
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Figure 10. CDK1 and CDK2 protein expression in FT282 cell lines. Western blot
analysis of CDK1 and CDK2 in the FT282 cells engineered for dox-inducible empty
vector control (57), FOXM1, CCNE1, or E1/F1 expression and grown for 24 hours in the
presence of 1 µg/mL dox. A. Western blot probing for CDK1 on the left, with the Image J
protein quantification on the right, and B. Western blot probing for CDK2 on the left, with
Image J protein quantification on the right.
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Figure 11. Treatment of FT282 E1/F1 cells with dinaciclib results in a decrease of
p-FOXM1. Western blot analysis of p-FOXM1, total FOXM1, and CCNE1 in the FT282
cells engineered for dox inducible E1/F1 expression. Cells were grown for 24 hours in
the presence of 1 µg/mL dox, then treated with dinaciclib in 10 µM and 1 µM
concentrations. 24 hours after drug treatment, whole cell proteins were harvested and a
western blot analysis conducted. B. Quantification of the western blot analysis.
Treatment of cells, protein extraction, and western blotting were repeated twice. Bars
represent mean ± SD. Significant student’s t test p values are shown. P value
designation: * < 0.05. All other comparisons were not significant.
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Figure 12. Treatment of FT282 E1/F1 cells with R03306 results in an increase of pFOXM1. A. Western blot analysis of p-FOXM1, total FOXM1, CDK2, CDK1, and CCNE1
in the FT282 cells engineered for dox inducible E1/F1 expression. Cells were grown for
24 hours in the presence of 1 µg/mL dox, then treated with R03306 in 10 µM and 1 µM
concentrations. 24 hours after drug treatment, whole cell protein was harvested and a
western blot analysis conducted. B. Quantification of the western blot analysis.
Treatment of cells, protein extraction, and western blotting were repeated twice. Bars
represent mean ± SD. Significant student’s t test p values are shown. P value
designation: * < 0.05. All other comparisons were not significant.
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Figure 13. Treatment of FT282 E1/F1 cells with Palbociclib does not alter p-FOXM1
levels. A. Western blot analysis of p-FOXM1, total FOXM1, CDK2, CDK1, and CCNE1
in the FTE cells engineered for dox inducible E1/F1 expression. Cells were grown for 24
hours in the presence of 1 µg/mL dox, then treated with Palbociclib in 10 µM and 1 µM
concentrations. 24 hours after drug treatment, whole cell proteins were harvested and
used for western blot analysis. B. Quantification of the western blot data using Image J.
Treatment of cells, protein extraction, and western blotting were repeated twice. Bars
represent mean ± SD. Student’s t test performed, all comparisons were not significant.
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Figure 14. Treatment of FT282 E1/F1 cells with AT7519 results in a decrease in pFOXM1. A. Western blot analysis of p-FOXM1, total FOXM1, CDK2, CDK1, and CCNE1
in the FT282 cells engineered for dox inducible CCNE1/FOXM1 expression. Cells were
grown for 24 hours in the presence of 1 µg/mL dox, then treated with AT7519 in 0.1, 0.5,
1, and 10 µM concentrations. 24 hours after drug treatment, whole cell protein was
harvested and a western blot analysis conducted. B. Quantification of the western blot
analysis.
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Table 3. CDK inhibitor specificity and effect on p-FOXM1 levels in FT282 E1/F1
cells. The references for each inhibitor indicates the original study in which the CDK
inhibitor was discovered and the study determining the inhibitor’s CDK specificity, if
applicable. The effect on p-FOXM1 was determined in the current study (see Figures 1114).
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p-FOXM1, total FOXM1, CCNE1, and CDK2 protein expression in HGSC lines
Next, we determined the levels of p-FOXM1, total FOXM1, and CCNE1 in
clinically relevant cell line models of human HGSC. All the cell lines have Tp53
mutations and heterogeneous alterations in CCNE1 and FOXM1 pertinent to HGSC
(Table 4). In total, we surveyed nine human HGSC cell lines. We found that cyclin E1
was expressed in the majority of the HGSC lines and was localized to both the
cytoplasm and nucleus (Figures 15 and 16). CDK2 showed a similar pattern to cyclin E1,
as it was expressed in the majority of the HGSC cell lines and tended to show
expression in both the cytoplasm and nucleus. In contrast, total FOXM1 was expressed
in all HGSC lines but was present primarily in the nucleus (Figures 15 and 16).
Importantly, phosphorylated FOXM1 was detected in all HGSC cell lines and was
present primarily in the nucleus (Figures 15 and 16). These data suggest that activated
FOXM1 is a common phenotype of HGSC cell lines.
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Table 4. HGSC cell line genomic characteristics. TP53 indicates somatic mutation of
the Tp53 gene. Gene gain and amplification of FOXM1 was determined by GISTIC
(43,119). CCNE1 gain and amplification information was obtained from cBioPortal and
(120). In GISTIC, a numerical value of 0 indicates a diploid cell line, +1 indicates a lowlevel gain (a few additional copies of the gene), and a value of +2 indicates a high-level
amplification.
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Figure 15. p-FOXM1, total FOXM1, CCNE1, and CDK2 protein expression in HGSC
cell lines. Western blot analysis of p-FOXM1, total FOXM1, CCNE1, and CDK2 in
HGSC cell lines. Nuclear and cytoplasmic extracts were harvested 24 hours post
seeding. CE: cytoplasm extract, NE: nuclear extract
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Figure 16. Quantification of the levels of p-FOXM1, total FOXM1, CCNE1, and
CDK2 proteins in HGSC cell line nuclear extracts. Quantification of the Western blot
analyses of p-FOXM1, total FOXM1, CCNE1, and CDK2 in a HGSC cell line panel.
Nuclear and cytoplasmic extracts were harvested 24 hours post seeding. A.
Quantification of p-FOXM1 in nuclear extracts obtained from HGSC cell lines, B.
Quantification of total FOXM1 in the nuclear extracts of the HGSC cell lines, C.
Quantification of CCNE1 in the nuclear extracts of the HGSC cell lines and, D.
Quantification of CDK2 in the nuclear extracts of the HGSC cell lines.
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p-FOXM1, total FOXM1, CCNE1, and CDK2 protein expression in primary EOC
tumor samples
We next examined the expression patterns of the aforementioned proteins in
primary EOC tumors (Figure 17). We performed western blot analyses on whole cell
extracts from 43 tumor samples and used bulk normal ovary (NO) as a control tissue.
Interestingly, these proteins showed widespread but heterogeneous expression in
primary EOC (Figure 17). Next, to determine whether expression of the individual
proteins correlate, we quantified target band intensities using Image J, and performed
statistical correlation analyses. Notably, we found that the expression of all protein pairs
tested showed highly significant correlations. The strongest correlations were between
CDK2 and cyclin E1, followed by p-FOXM1 and CDK2 and p-FOXM1 and cyclin E1. A
moderately lower but still highly significant correlation was seen between p-FOXM1 and
FOXM1, FOXM1 and CDK2, and FOXM1 and cyclin E1 (Figure 18). A summary of the
comparisons and corresponding Spearman correlations is presented in Table 5. To
further illustrate the degree of protein correlations, we arranged protein expression in the
tumors by descending p-FOXM1 tumor expression. As shown in Figure 19, there was a
similar decreasing protein expression pattern observed for total FOXM1, cyclin E1, and
CDK2.
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Figure 17. Western blot analyses of p-FOXM1, total FOXM1, cyclin E1, and CDK2
expression in normal ovary and primary EOC tumor samples. Western blot analyses
of whole cell extracts for p-FOXM1, cyclin E1, and CDK2 in primary tumor samples
obtained from patients undergoing surgical resection at RPCCC. NO is a bulk normal
ovary sample that serves as a control and is denoted by the red outlined box. EOC are
epithelial ovarian cancer samples and the number is the patient identification number.
We surveyed a total of 43 EOC samples.
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Figure 18. Correlations between p-FOXM1, total FOXM1, CCNE1, and CDK2 protein
expression in primary EOC tumor samples. Spearman correlation analyses were
performed using western blot data from primary EOC samples obtained from patients
undergoing surgical resection at RPCCC (Figure 18). A. Cyclin E1 vs. CDK2. B. CDK2
vs. p-FOXM1. C. Cyclin E1 vs, p-FOXM1. D. FOXM1 vs. p-FOXM1 protein levels. E.
CDK2 vs. FOXM1. F. Cyclin E1 vs. FOXM1. Target protein expression was normalized
to β-actin prior to performing the correlation analysis.
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Table 5. Spearman correlations between p-FOXM1, total FOXM1, cyclin E1, and
CDK2 protein expression in primary EOC tumor samples. Data were obtained
from western blotting of whole cell extracts. Protein comparisons are listed in
descending order of Spearman coefficients.
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Figure 19. p-FOXM1, total FOXM1, cyclin E1, and CDK2 protein expression in
primary EOC samples, arranged in descending order of p-FOXM1 expression. Data
obtained through quantification of western blot analyses of primary EOC samples obtained
from patients undergoing surgical resection at RPCCC. A. p-FOXM1, B. total FOXM1, C.
Cyclin E1, and D. CDK2. Protein expression levels are displayed in order of descending
p-FOXM1 expression.
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Dinaciclib treatment reduces the levels of phosphorylated FOXM1 in OVCAR8
HGSC cells
Next, we determined the effect of dinaciclib treatment on p-FOXM1 levels in
OVCAR8 cells. Dinaciclib was chosen based on its robust inhibitory effect observed in
the FT282 cell model (Figure 11). In addition, we chose OVCAR8 as a cell model
because it showed high expression of the proteins under examination (p-FOXM1, total
FOXM1, CCNE1, and CDK2) (Figures 15 and 16). Notably, dinaciclib treatment
profoundly affected the levels of p-FOXM1 and CDK2 in OVCAR8 nuclear extracts,
decreasing p-FOXM1 levels two-fold and CDK2 levels ten-fold (Figure 20). Additionally,
the nuclear levels of total FOXM1 and cyclin E1 also decreased with dinaciclib treatment
(Figure 20).
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Figure 20. Treatment of OVCAR8 cells with dinaciclib results in a decrease of pFOXM1. A. Western blot analyses of p-FOXM1, total FOXM1, Cyclin E1, and CDK2 in
the OVCAR8 HGSC cell line. Cells were seeded in duplicate and treated 24 hours post
seeding with Dinaciclib (10 µM and 1 µM concentrations) and a DMSO control. Nuclear
(NE) and cytoplasmic extracts (CE) were harvested 24 hours after drug treatment. The
positive control was the FT282 E1/F1 cells and is denoted by a +. B. Quantification of
the p-FOXM1, total FOXM1, cyclin E1, and CDK2 protein expression levels in OVCAR8
nuclear extracts. Bars represent mean ± SD. Significant student’s t test p values are
shown. P value designation: * < 0.05.
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Transformation characteristics of FT282 cells engineered for ectopic expression
of CCNE1, FOXM1 or both proteins.
Next, to determine what phenotypic role ectopic expression of FOXM1 and
CCNE1 may play in HGSC oncogenesis, we measured transformation characteristics
using engineered FT282 cells. Supporting these investigations, both CCNE1 and
FOXM1 are expressed in pre-neoplastic lesions in the distal FTE (39, 83). Utilizing the
FT282 model system, we measured cell proliferation, migration, invasion, and
clonogenic growth characteristics.
Cell proliferation assays revealed that the dually expressing E1/F1 FT282 cell
line has increased proliferation in comparison to the empty vector control or singly
expressing (E1 or F1) lines (Figure 21). The empty vector cells grew the slowest, with
the singly expressing lines displaying similar trajectories of growth that were significantly
greater than the vector control.
Cell migration assays revealed that the E1/F1 cells migrated most efficiently,
followed by FOXM1 expressing cells, CCNE1 expressing cells, and vector control cells
(Figure 22). Furthermore, the invasive properties of the cell lines was highly similar to
the migratory capacity (Figure 23). Finally, all ectopic expression cell lines showed
clonogenic growth that was highly elevated over vector control cells, but the individual
lines were each similar (Figure 24).
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Figure 21. E1/F1 ectopic expression FT282 cells show a higher proliferation rate
than FOXM1 or CCNE1 expressing cells. FT282 cells engineered for dox inducible
empty vector control (57), FOXM1, CCNE1, or E1/F1 expression were seeded at a density
of 20,000 cells per well into 6-well plates, seeding each cell line in triplicate. A plate was
seeded for each day of counting. 24 hours post seeding, the media was replaced with
media containing 1 µg/mL dox. The media with dox was replenished every 48 hours. The
following procedure was used to count the cells: the wells were washed with room
temperature PBS, trypsinized, centrifuged at 500g for five minutes, resuspended in one
mL of media, and counted using a Bio Rad TC20 automated cell counter. Total cells were
counted every 24 hours for 5 days. Bars represent mean ± SD. Two-way ANOVA p values
are shown. P value designations: **** < 0.0001, *** < 0.001, ** < 0.01.
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Figure 22. E1/F1 ectopic expression FT282 cells show higher rates of cell
migration compared to FT282 cells with CCNE1 or FOXM1 expression alone. A
Corning migration assay was performed on FT282 cells engineered for dox-inducible
empty vector control (57), FOXM1, CCNE1, or E1/F1 expression. Approximately
250,000 cells suspended in media containing 1 µg/mL dox were added into control
chambers. The chambers were placed into wells containing media with chemoattractant
and 1 µg/mL of dox. After 22 hours of incubation, the chambers were fixed with 100%
methanol, stained with 0.5% crystal violet, and visualized with a light microscope at 100x
magnification. A. Representative images of the migration assay in the indicated FT282
cells. Purple stained cells indicate cells that have migrated through the control insert,
white circles indicate pores. B. Quantification of migrated cells in the FT282 cell lines
(n=5). Bars represent mean ± SD. Student’s t test p values are shown. P value
designations: **** < 0.0001, *** < 0.001.
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Figure 23. E1/F1 ectopic expression FT282 cells show higher rates of invasion
compared to FT282 cells with CCNE1 or FOXM1 expression alone. A Corning
Biocoat Matrigel assay was performed on the FT282 cells engineered for dox-inducible
empty vector control (57), FOXM1, CCNE1, and E1/F1 expression. Approximately
250,000 cells suspended in media containing 1 µg/mL of dox were added into Biocoat
Matrigel chambers. The chambers were placed into wells containing media with
chemoattractant and 1 µg/mL dox. After 22 hours of incubation, the chambers were fixed
with 100% methanol, stained with 0.5% crystal violet, and visualized with a light
microscope at 100x magnification. A. Representative images of the invasion assay in the
FT282 cell lines. Purple stained cells indicate cells that have invaded through the
Matrigel insert, white circles indicate pores. B. Quantification of migrated cells in the
FT282 cell lines (n=5). Bars represent mean ± SD. Student’s t test p values are shown.
P value designations: ** < 0.01, * < 0.05.
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Figure 24. Clonogenic growth (i.e. colony formation) assay of FT282 cells with
ectopic CCNE1, FOXM1, or E1/F1 expression. A. FT282 cells engineered for doxinducible empty vector control (57), FOXM1, CCNE1, and E1/F1 expression. were
seeded into 6-well plates, in triplicate, at a density of 500 cells per well. 1 µg/mL of dox
was added to the media 24 hours post seeding and was replenished every 48 hours.
Colony formation was measured after eight days, and the cells were fixed in methanol
and stained with crystal violet. B. Colonies containing greater than 50 cells were counted
and clonogenic survival was quantified as an average of three replicates. Bars represent
mean ± SD. Student’s t test p values are shown. P value designations: **** < 0.0001,
*** < 0.001, ** < 0.01. Experiments were repeated five times.
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CHAPTER 4: DISCUSSION

FOXM1 pathway activation is the second most common molecular alteration in
HGSC, after Tp53 mutation, and CCNE1 is amplified and overexpressed in 20% of
HGSC cases. Both FOXM1 and cyclin E1 have been extensively studied in cancer, but
the potential interaction of the two proteins in HGSC progression, or in any other cancer
model system, has not previously been addressed. A previous study showed that
CCNE1/CDK2 complexes phosphorylate FOXM1 and identified 3 amino acid residues
within the FOXM1 protein that are CCNE1/CDK2 phosphorylation sites (65). The
phosphorylation of FOXM1 is critical, as phosphorylation results in functional activation
of FOXM1 as a transcription factor. Moreover, we previously reported strong correlations
between FOXM1 and CCNE1/Cyclin E1 mRNA and protein expressions in TCGA data,
and showed that ectopic expression of CCNE1 in FTE cells resulted in increased
FOXM1 expression (43). Further investigation into the CCNE1/CDK and FOXM1
interaction in the context of HGSC has not been investigated and provided the impetus
for our studies.
Herein, we report several key findings relevant to CCNE1/CDK and FOXM1 and
their functional interactions in HGSC: 1. Expression of p-FOXM1 was seen only in the
CCNE1 and FOXM1 dual expression cell line. 2. CCNE1 and FOXM1 are expressed
prior to p-FOXM1 expression in the dual expression CCNE1 and FOXM1 FTE line. 3.
CDK1 and CDK2 are both expressed in the FT282 cell models, however drug treatments
with CDK inhibitors implicate CDK2 as the primary CDK that mediates cyclin E1mediated phosphorylation of FOXM1. 4. p-FOXM1, total FOXM1, cyclin E1, and CDK2
are all expressed in HGSC cell lines, with p-FOXM1 and FOXM1 localized primarily to
the nucleus. 5. Treatment with a CDK inhibitor (dinaciclib) decreases p-FOXM1 nuclear
levels in a HGSC cell line. 6. p-FOXM1, total FOXM1, CCNE1, and CDK2 are expressed
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in primary EOC tumor samples, and each of the protein pairs show strongly correlated
expression. 7. Ectopic expression of CCNE1 and FOXM1 drives key transformative
phenotypes in FT282 cells including cell proliferation, migration, invasion, and
clonogenic growth. Critically, for all but one of the assessed phenotypes, dual
expression cells showed significantly stronger transformative properties than did single
ectopic expression cells.
Three CCNE1/CDK2 phosphorylation sites in FOXM1 were reported previously
(65). We confirmed that one of these phosphorylation sites (threonine 600) is
phosphorylated as a result of the formation of the CCNE1/CDK complex in FTE cells, as
the p-FOXM1 species was observed in only the CCNE1/FOXM1 overexpressing FTE
cell line. p-FOXM1 is also detected at a later timepoint, after both CCNE1 and FOXM1
are expressed. Therefore, the formation of p-FOXM1 occurs only in the dually
expressing line, and it is contingent upon the earlier production and accumulation of
sufficient levels of both FOXM1 and cyclin E1.
We investigated the impact of CDK inhibitors on phosphorylation of FOXM1.
Dinaciclib shows promise as a cancer drug and has been used in both Phase II and
Phase III clinical trials in various cancers, with promising results in the treatment of
lymphomas and leukemia (121, 122, 123). We confirmed that both CDK1 and CDK2 are
expressed in FT282 cell lines, with a slight increase in expression in CCNE1
overexpressing and CCNE1/FOXM1 overexpressing lines. After treating the FT282
E1/F1 line with dinaciclib, we observed a profound reduction in p-FOXM1. There is
evidence in the literature that CDK1 can compensate for loss of CDK2, so confirmation
of CDK2 as the primary partner with CCNE1 was needed (103). As a CDK2 selective
inhibitor is not currently available, we utilized additional CDK inhibitors with differing
specificities: R03306 (CDK1 inhibitor), Palbociclib (CDK4 and 6 inhibitor), and AT7519
(CDK1, 2, 4, 6, and 9) (Table 3). To test the role of CDK1 in the CCNE1-mediated
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phosphorylation of FOXM1, we used R03306, a CDK1 inhibitor. Interestingly, R03306
caused an unexpected increase in p-FOXM1 levels in FT282 E1/F1 cells. We speculate
that CDK1 may complex with CCNE1 and once CDK1 is blocked by this drug, a
compensatory mechanism comes into play. A potential mechanism is that when CDK1 is
unable to bind with CCNE1, more CCNE1 is available for binding with CDK2, and this
results in increased phosphorylation of FOXM1. In this scenario, CDK1/CCNE1 may not
target FOXM1 for phosphorylation, may target a distinct site on FOXM1 not recognized
by our antibody, or may be significantly less efficient than CDK2/CCNE1 complexes for
targeting FOXM1.
To further confirm that CDK2 is the main binding partner of CCNE1 that mediates
phosphorylation of FOXM1, we treated FT282 E1/F1 cells with Palbociclib (a CDK4 and
6 inhibitor) and AT7519 (a CDK1, 2, 4, 6, and 9 inhibitor). We expected little to no
decrease in FOXM1 phosphorylation with Palbociclib treatment, as it targets CDK4 and
6, and this is indeed what we observed. Conversely, we expected a decrease of pFOXM1 when AT7519 was used. As expected, AT7519 treatment led to a decrease in
p-FOXM1, lending further support to the hypothesis that CDK2 may be the main CDK
complexing with CCNE1 to phosphorylate FOXM1. In the future, generation of CDK1
and CDK2 knockdown cell lines may help further elucidate the nature of CCNE1mediated FOXM1 phosphorylation. This knowledge may be therapeutically relevant, as it
will aid in drug selection to impair FOXM1 function in HGSC. Furthermore, we can’t rule
out CDK9 as a potential CDK in the CCNE1-mediated phosphorylation of FOXM1. Both
CDK inhibitors that showed a reduction in p-FOXM1, dinaciclib and AT7519, block
CDK9. There is no literature that supports CCNE1 complexing with CDK9, but usage of
a CDK9 specific inhibitor would verify that the phosphorylation of FOXM1 is not through
a CCNE1 and CDK9 complex.
To further confirm the relevance of the CCNE1 and FOXM1 interaction in ovarian
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cancer, we determined the levels of p-FOXM1, FOXM1, cyclin E1, and CDK2 in a panel
of HGSC cancer cell lines. We found that p-FOXM1, FOXM1, cyclin E1, and CDK2 were
all present in the cancer cell lines, with FOXM1 located primarily in the nucleus. These
data indicate that in HGSC lines, the principal proteins relevant to FOXM1 activation are
present. Importantly, we also observed that FOXM1 is activated in many HGSC cell
lines, as indicated by its nuclear localization and by the detection of p-FOXM1 in the
nucleus, with phosphorylation at residue threonine 600. The copy number of FOXM1
and CCNE1 did not appear to correlate well with the respective protein expression in
HGSC cell lines (data not shown).
To expand the above findings, we measured the level of p-FOXM1, FOXM1,
cyclin E1, and CDK2 in primary epithelial ovarian cancer (EOC) tumor samples. All
proteins were expressed, but with variable levels in tumors. We further determined the
correlations between individual proteins. Notably, all of these related proteins
significantly correlated with each other. The strongest correlations were found between
CDK2 and cyclin E1, followed by p-FOXM1 and CDK2 and p-FOXM1 and cyclin E1.
These results support that p-FOXM1 is strongly dependent on cyclin E1 and CDK2
levels, and that cyclin E1 levels are correlated with CDK2 levels, which is expected as
the two proteins form a complex. To fully understand the significance of the correlations,
further investigation into the EOC samples is needed. Western blotting and subsequent
Spearman correlation analysis for non-related or antagonistic proteins, such as different
CDKs or FOX family members, will help to place the observed correlations into better
context.
Of the CDK inhibitors used, dinaciclib treatment caused the greatest decrease in
p-FOXM1 levels in engineered FT282 cells; therefore we tested its ability to reduce pFOXM1 in HGSC cells. As an experimental model, we used OVCAR8 HGSC cells,
which displayed very high levels of p-FOXM1 among a panel of HGSC cell lines.
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Dinaciclib treatment significantly decreased the amount of p-FOXM1 and CDK2 in the
nuclear extracts from OVCAR8 cells. The effect that the other CDK inhibitors may have
on p-FOXM1 in HGSC cell lines should be investigated in future studies. In addition, the
effect of dinaciclib on p-FOXM1 in other HGSC cell lines should be assessed.
The diminution of CDK2 nuclear protein levels in OVCAR8 cells after dinaciclib
treatment is interesting and suggests that inhibition of a CDK results in a decrease in its
nuclear concentration, which warrants further investigation. Looking at the nuclear
versus cytoplasmic levels of CDK1 and 2 in the nuclear and cytoplasmic extracts of
FT282 cell lines, and in additional HGSC cell lines treated with dinaciclib, will help reveal
the significance of the above observation. It is plausible that dinaciclib works not only by
inhibiting CDK enzymatic activity but also by leading to the degradation of CDK2 or by
causing a decrease of its transport into the nucleus.
Dinaciclib, with its effects seen in both the FT282 and HGSC cell models, has
shown encouraging results blocking phosphorylation of FOXM1 and thus, preventing the
activation of FOXM1. This, combined with its use in cancer clinical trials, suggests that it
has potential as a therapeutic agent in CCNE1 amplified HGSC (124). More inquiries
into dinaciclib effects in HGSC are needed, such as treatments at varying timepoints, to
observe its impact on FOXM1 phosphorylation over time. In addition, whether the
biological effects of dinaciclib in HGSC are related to its impact on FOXM1
phosphorylation should be determined.
Conversely, R03306 may also be an intriguing prospect in treating HGSC. As
shown here, R03306 treatment increases the levels of p-FOXM1, indicating that a
compensatory mechanism continues phosphorylating FOXM1 in the absence of CDK1
activity. Interestingly, too much p-FOXM1 could prove to be deleterious to the cell, by
pushing cells through the cell cycle inappropriately and inducing mitotic catastrophe.
Mitotic catastrophe is a result of aberrant mitosis and leads to cell death through
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apoptosis or necrosis (125). Thus, treatment with R03306 and subsequent induction of
p-FOXM1 could result in mitotic catastrophe of cancer cells, as they progress through
the cell cycle improperly.
Phenotypic assays were performed to investigate the role of CCNE1 and FOXM1
in FTE cellular transformation. Ectopic expression of CCNE1 and FOXM1 in FT282 cells
promoted an increase in cellular proliferation, migration, and invasion in comparison to
the vector control and singly expressing FT282 cell lines. However, unlike the other
transformation phenotypes, the E1/F1 FT282 overexpressing line did not show
increased colony formation compared to single ectopic expression cell lines, suggesting
the mechanisms involved in this particular phenotype are distinct.
These data underscore that CCNE1 and FOXM1, as well as cyclin E1 dependent
phosphorylation of FOXM1, plays a role in FTE cell proliferation, invasion, and migration,
but are not as integral in colony formation. Interestingly, FOXM1 seems to be important
in invasion and migration, which is consistent with our unpublished observations of the
gene expression signatures in FT282 cells engineered for dual E1/F1 ectopic
expression. This is an important observation, as invasion and subsequent metastasis
account for 90% of mortality in solid cancers. There are classes of anti-invasion
treatments, such as matrix metalloprotease inhibitors and drugs targeting actin and
myosin, which could show promise in HGSC, as FOXM1 is a major contributor to these
processes (126).
In summary, we have investigated the interplay between FOXM1 and CCNE1
using FTE and HGSC models. We show for the first time that cyclin E1 promotes the
phosphorylation of FOXM1 in HGSC, and show that this event is likely relevant both in
vitro and in vivo. We also provide evidence that CDK2 is the key kinase that complexes
with CCNE1 to mediate p-FOXM1 at residue threonine 600. Importantly, we
demonstrate that FOXM1 and CCNE1 work together to drive critical transformation
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phenotypes, including migration and invasion. Future studies will examine the
importance of the functional interactions of FOXM1, cyclin E1, and CDK2 in HGSC
biology and treatment.
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